Allergy Shot for Seasonal Allergies: There Is No Single Shot — Here Is Why
A single allergy shot for seasonal allergies does not deliver clinical benefit — SCIT requires a 60-to-80-injection multi-year course to reach and sustain an effective maintenance dose per Cox 2011 PP3. Patients asking for 'one shot' usually mean the IM depot corticosteroid (Kenalog-40/Depo-Medrol) — a symptomatic product delivering 1–3 weeks of relief that the AAAAI/ACAAI rhinitis Practice Parameter actively discourages. FDA-approved SLIT tablets (Grastek/Ragwitek) are daily oral disease-modifying alternatives requiring only one clinic visit. Curex's at-home allergy shot program turns the full SCIT course into a weekly home injection with pricing confirmed in a current program quote — the disease-modifying outcome without the weekly clinic visit burden.
9 peer-reviewed sources
There is no single allergy shot for seasonal allergies that provides disease modification — SCIT is a 60-to-80-injection course. A depot steroid shot (Kenalog/Depo-Medrol) exists but is symptomatic, lasts 1–3 weeks, and is professionally discouraged for routine seasonal AR.
Key facts
A 2026 observational cohort of 2,897 patients on at-home sublingual immunotherapy reported clinically meaningful improvement rising from 28% at 12 months to 45% at 24 months, showing how benefit accrues with time on treatment rather than arriving early.
The essentials
An allergy shot for seasonal allergies — singular — reflects a question many patients bring to their allergist or search engine: "Is there one shot I can get for my seasonal allergies?" The honest answer is: a single SCIT injection on its own has no documented clinical effect. SCIT efficacy requires reaching and sustaining an effective maintenance dose of allergen extract over a 3–5 year course comprising approximately 60–80 injections. A single injection delivers a sub-therapeutic dose that does not modify the immune program.
Curex's at-home IgE testing identifies the specific seasonal pollens behind a patient's symptoms, with allergist review to determine whether SCIT or an FDA-approved SLIT tablet is appropriate. For eligible patients choosing SCIT, Curex offers a home-based shot program with pricing confirmed in a current program quote — the 60-to-80-injection disease-modifying course, self-administered weekly at home with the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff.
The patient asking for "one shot" is usually thinking of one of two things: the IM depot corticosteroid (Kenalog-40 triamcinolone acetonide or Depo-Medrol methylprednisolone acetate) — a real, FDA-approved product that some urgent-care and primary-care offices still offer annually for hay fever. The Depo-Medrol label specifies: "an intramuscular dose of 80 to 120 mg may be followed by relief of coryzal symptoms within six hours persisting for several days to three weeks." This is symptomatic anti-inflammatory suppression — not immunotherapy, not disease-modifying, and not approved for ongoing preventive use. The AAAAI/ACAAI rhinitis Practice Parameter discourages single parenteral steroid administration for routine seasonal AR and contraindicates recurrent administration due to hypothalamic-pituitary-adrenal (HPA) axis suppression and adrenal-axis risk. Kenalog-40 was first FDA-approved on February 1, 1965, and its label lists seasonal AR only among "allergic states intractable to adequate trials of conventional treatment."
The appropriate path when pharmacotherapy fails: the Cox 2011 PP3 indication threshold for SCIT or SLIT is when symptoms persist or worsen despite adequate avoidance and pharmacotherapy, and when IgE sensitization to a clinically relevant allergen is documented. This is the decision point that warrants a board-certified allergist evaluation, not an urgent-care steroid injection.
For patients with single-allergen sensitization (timothy grass or short ragweed monosensitization) who want a disease-modifying option without a multi-year injection series, FDA-approved SLIT tablets offer a legitimate route: Grastek (timothy grass, ALK, ages 5–65) and Ragwitek (short ragweed, Merck, ages 5–65 after 2021 expansion) are taken daily at home after one supervised first-dose clinic visit. Both carry boxed warnings for anaphylaxis and require epinephrine co-prescription. The schedule — one supervised first dose, then daily home dosing — is the closest thing to a practical "minimal-clinic-visit" disease-modifying option for specific pollen allergens.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
SCIT efficacy for seasonal allergic rhinitis is well-established — but only for patients who complete the multi-injection course.
Curex's at-home allergy shots work differently than a steroid shot
If steroid shots or medications aren't cutting it, Curex offers at-home allergy immunotherapy with clinician support.
See if you qualifyCurex allergy shot serum is compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
Frequently asked questions
Is there a once-a-year allergy shot for seasonal allergies?
The only single-dose injection sometimes given for seasonal allergies is a depot corticosteroid — Kenalog-40 (triamcinolone acetonide IM) or Depo-Medrol (methylprednisolone acetate IM) — which delivers symptomatic relief for approximately 1-3 weeks. This is not immunotherapy and the AAAAI/ACAAI rhinitis Practice Parameter discourages it for routine seasonal AR. There is no FDA-approved 'once-a-year' allergen immunotherapy injection. The closest low-visit-burden disease-modifying option is an FDA-approved SLIT tablet, which requires only one supervised first-dose clinic visit and is then taken daily at home.
What is a Depo shot (Depo-Medrol) for allergies and what are the types of steroid shots for allergies?
Depo-Medrol (methylprednisolone acetate) and Kenalog (triamcinolone acetonide) are the two depot corticosteroid injections most commonly used for a severe seasonal allergy flare. Both are intramuscular, long-acting steroids that suppress inflammation systemically for roughly 1-3 weeks rather than changing the underlying allergic response. Professional allergy societies discourage routine use of either because they are not disease-modifying and carry cumulative risks like adrenal suppression with repeated use — immunotherapy (SCIT or SLIT) is the disease-modifying alternative.
Why does SCIT require so many shots instead of just one?
SCIT is dose-driven: the immune system requires graduated exposure to escalating allergen concentrations over many months to safely reprogram from an IgE-mediated allergic response toward regulatory T-cell mediated tolerance. Starting at a maintenance-level dose without build-up would produce unacceptable systemic-reaction rates — the extract begins at roughly 1:100,000 of the maintenance concentration for safety. Reaching maintenance doses for seasonal pollens from initial dilutions takes approximately 26-28 weekly incremental injections.
What is Kenalog and why do allergists discourage it for seasonal allergies?
Kenalog-40 (triamcinolone acetonide 40 mg/mL, IM injection) is a long-acting depot corticosteroid. It reduces allergic inflammation by suppressing downstream immune activity, providing symptomatic relief for several days to approximately three weeks. Professional allergy societies discourage its routine use for seasonal AR because it is not disease-modifying, systemic corticosteroid exposure causes cumulative hormonal and bone-density risks with recurrent use, and disease-modifying alternatives like SCIT and SLIT exist.
What is the Cox 2011 indication for switching from antihistamines to allergy shots?
The Cox 2011 Practice Parameter states that subcutaneous or sublingual immunotherapy should be considered when symptoms persist or worsen despite adequate allergen avoidance and pharmacotherapy, and when IgE sensitization to a clinically relevant allergen is documented. In practical terms: a patient with moderate-to-severe seasonal AR not adequately controlled by a second-generation antihistamine plus intranasal corticosteroid, with a positive allergy test, meets the threshold for an immunotherapy evaluation.
Are SLIT tablets closer to a single-visit treatment?
SLIT tablets approved by the FDA require only one supervised first-dose clinic visit; subsequent dosing is daily at home. This makes them the lowest clinic-visit-burden disease-modifying option for seasonal pollen allergic rhinitis — but they require daily compliance at home for 3-5 years and are not single-dose products. They carry boxed warnings for anaphylaxis requiring the supervised first dose and require co-prescription of epinephrine. They are not available for tree pollens or most weeds other than ragweed; polysensitized patients typically require SCIT rather than a tablet product.
What should I do if antihistamines and nasal sprays stop working for seasonal allergies?
When intranasal corticosteroids and second-generation antihistamines fail to control seasonal allergic rhinitis — particularly when symptoms significantly impair quality of life, sleep, or work across two or more consecutive pollen seasons — the appropriate next step is evaluation by a board-certified allergist. The allergist will confirm IgE sensitization via testing, identify which allergens are driving symptoms, and determine whether SCIT, an FDA-approved SLIT tablet, or another therapy is appropriate.
How effective is the allergy shot for seasonal allergies compared to daily medication?
Cochrane meta-analysis data on SCIT for seasonal allergic rhinitis found a clinically meaningful symptom reduction versus placebo. Unlike daily medication, SCIT benefits persist 3-12 years after stopping the full course, meaning the 3-5 year investment converts to a decade of potential benefit. The pediatric PAT study documented a meaningful reduction in asthma incidence at long-term follow-up, an effect no antihistamine or intranasal steroid produces. The comparative advantage of SCIT is that it changes the immune program; pharmacotherapy only suppresses symptoms while taken.
Related Articles
Allergy Injections Guide: Schedule & Safety | Curex
Allergy injections (SCIT) mean 60-80+ visits over 3-5 years. Cochrane 51 RCTs: SMD -0.73. Learn what goes in the vial, the schedule, and real-world adherence data.
Read moreAllergy Shots for Pollen: Who Qualifies | Curex Guide
Yes, allergy shots target pollen via SCIT. Cox 2011 candidacy threshold, FDA SLIT tablets, per-allergen efficacy, and Curex at-home shots — all covered.
Read moreAllergy Shots vs Drops: Evidence-Based Comparison | Curex
Allergy shots (SCIT) vs sublingual drops (SLIT): comparable efficacy per Nelson 2015, but SLIT has zero fatalities vs 1 per 2.5M shots. Full comparison.
Read moreAllergy Shots for Tree Pollen: Birch, Oak & Cedar | Curex
Tree SCIT: birch 40% reduction (Bødtger 2002), Bet v 1 / PR-10 cross-reactivity, OAS, cedar gap. Curex at-home shots cover birch, oak, cedar.
Read moreAllergy Desensitization: SCIT Guide & History | Curex
Allergy desensitization is the historical term for SCIT (allergen immunotherapy). Cochrane 51 RCTs: SMD -0.73. Learn the terminology shift from 1911 to today.
Read moreGet your allergy shots — without the clinic.
Curex at-home shots require a program quote. Confirm what is included in your plan — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
Program quote required · Remaining payments for shipped treatment are collected on cancellation
Curex allergy shot serum is compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.